News | March 01, 2023
AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Dr Ratna Puri from Sir Ganga Ram Hospital, Delhi is the Chairperson of the expert committee.
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
Subscribe To Our Newsletter & Stay Updated
